Van Herk Investments
Van Herk Ventures invests in the life sciences sector through direct investments in private and listed companies and in venture capital funds. For listed companies we can focus globally and for the private companies and venture capital funds we focus on the Benelux.
Van Herk Investments invests in both listed and unlisted companies. The investment focus is on the construction, project development, biotechnology, financial services and energy sectors. For listed investments we look at shares all over the world from small to very large companies. For investments in non-listed companies we concentrate on the Benelux and we usually participate in companies with an enterprise value between € 10 and € 150 million at the time of the first participation.
Sector
18 past transactions
Sensara B.V.
Series A in 2017
Sensara empowers senior citizens and vulnerable people to enjoy their independence in a safe and healthier manner. Sensara alerts, signals and advices family and/or caregivers when needed. How? Our self-learning algorithms monitor 30 medically verified profiles against the information received from our sensors. The information is send to our user-friendly apps and interfaces. We believe that by knowing better what is going on, we can take care in better way. Off course, every client is always in control of their own data and privacy.
Our modular product line offers solutions integrated seamlessly from your own home, independent and assisted living, until nursing home. Knowing your history can improve your care in the future.
Vitalnext
Funding Round in 2013
VitalneXt B.V. develops products with evidence-based health benefits for the ageing population. It offers Promanna, a product for orally administered active small molecules; L-Proline, which exerts several positive effects in organisms under stress; D-Mannitol, a sugar with health promoting effects stretching back to biblical times; and Vital01, a product for elderly who suffer from malnutrition. The company was founded in 2013 and is based in Amersfoort, the Netherlands.
DCPrime B.V.
Corporate Round in 2014
DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based vaccines share all immune‐stimulatory properties with patient-derived dendritic cell‐based vaccines, and have the simple logistics of off‐the‐shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.
Isobionics
Venture Round in 2014
Isobionics B.V. develops, produces, and sells natural products for customers in flavor and fragrance market. It produces compounds, such as citrus oils that include lemon, orange, and grapefruit; compounds, including valencene and nootkatone, menthol, sandalwood oil, and patchouli oil; and other basic building blocks for the flavor and fragrance industry. The company was founded in 2008 and is based in Geleen, the Netherlands. As of September 26, 2019, Isobionics B.V. operates as a subsidiary of BASF SE.
Ceradis B.V.
Venture Round in 2019
Ceradis B.V. develops and markets plant nutrition and crop protection products. It also provides crop formulation services. The company serves the agricultural industry in the Netherlands and internationally. Ceradis B.V. was founded in 2005 and is based in Wageningen, the Netherlands with an additional office in Bogotá, Colombia.
SkylineDx
Venture Round in 2021
SkylineDx is an emerging commercial-stage company focused on the development and commercialization of innovative gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or to predict a patient’s response to a specific treatment.
Medis Medical Imaging Systems BV
Venture Round in 2018
Medis is a provider of post-processing software for the quantification of cardiovascular images. Medis' mission is to empower medical professionals by providing software that gives them the facts.
DCPrime B.V.
Venture Round in 2018
DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based vaccines share all immune‐stimulatory properties with patient-derived dendritic cell‐based vaccines, and have the simple logistics of off‐the‐shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.
Agendia, Inc.
Series D in 2007
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Agendia, Inc.
Private Equity Round in 2012
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
NightBalance B.V.
Series A in 2013
NightBalance B.V. develops and markets an obstructive sleep apnea (OSA) device for the treatment of positional obstructive sleep apnea to customers in Europe. It develops Sleep Position Trainer (SPT), which measures the sleep behavior of the patient continuously; gives a gentle vibration once the patient turns into the supine position; and reminds the patient to change their sleeping position without disrupting their natural sleeping architecture. The company was founded in 2009 and is based in The Hague, the Netherlands. As of May 8, 2018, NightBalance B.V. operates as a subsidiary of Koninklijke Philips N.V.
NightBalance B.V.
Series B in 2016
NightBalance B.V. develops and markets an obstructive sleep apnea (OSA) device for the treatment of positional obstructive sleep apnea to customers in Europe. It develops Sleep Position Trainer (SPT), which measures the sleep behavior of the patient continuously; gives a gentle vibration once the patient turns into the supine position; and reminds the patient to change their sleeping position without disrupting their natural sleeping architecture. The company was founded in 2009 and is based in The Hague, the Netherlands. As of May 8, 2018, NightBalance B.V. operates as a subsidiary of Koninklijke Philips N.V.
Agendia, Inc.
Series E in 2009
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Galapagos
Post in 2014
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.
Value and Budget Housing Corporation
Venture Round in 2015
VBHC is a professionally managed real estate company with marquee investors. They are privileged that India's largest home financer, Housing Development Finance Corporation (HDFC), is an anchor equity investor in VBHC.
SkylineDx
Venture Round in 2014
SkylineDx is an emerging commercial-stage company focused on the development and commercialization of innovative gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or to predict a patient’s response to a specific treatment.
Vastned
Post in 2017
Vastned is a listed European retail property company (Euronext Amsterdam: VASTN) focusing on ‘venues for premium shopping’. Vastned invests in selected cities in Europe with a clear focus on the best retail property in the most popular high streets in the bigger cities. Vastned's tenants are strong and leading international and national retail brands. The property portfolio had a size of approximately € 1.5 billion as at 30 June 2020.
SkylineDx
Venture Round in 2019
SkylineDx is an emerging commercial-stage company focused on the development and commercialization of innovative gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or to predict a patient’s response to a specific treatment.